<!DOCTYPE html>
<html>
  <head>
    <title>Cost Effective Analysis of Second Line Therapies in Relapsed Refractory Multiple Myeloma in Indian Scenario</title>
    <meta charset="utf-8">
    <meta name="author" content="Suman Kumar, Army Hospital (Research &amp; Referral), New Delhi" />
    <meta name="date" content="2017-02-10" />
    <link href="libs/remark-css/default.css" rel="stylesheet" />
    <link href="libs/remark-css/default-fonts.css" rel="stylesheet" />
    <link rel="stylesheet" href="my.css" type="text/css" />
  </head>
  <body>
    <textarea id="source">
class: center, middle, inverse, title-slide

# Cost Effective Analysis of Second Line Therapies in Relapsed Refractory Multiple Myeloma in Indian Scenario
## @ Indian Myeloma Congress, 2018
### <strong>Suman Kumar</strong>, Army Hospital (Research &amp; Referral), New Delhi
### 10 Feb 2017

---






class: center, middle, inverse

# Introduction

---

# Background

- Incurable malignancy of plasma cells

- Most patients diagnosed above 55 years

- **Chronic disease** with **multiple remissions and relapses**

- **Negative impact** on patient's overall **health related QoL**

---

# Relapsed Refractory Multiple Myeloma

- Improved survival in past 20 years (5 years survival 29.2% in 
1992 to 50.2% in 2012)&lt;sup&gt;1&lt;/sup&gt;

- It remains incurable with multiple relapses with multiple lines of treatment

- **Very poor prognosis** with median OS of 9 months&lt;sup&gt;2&lt;/sup&gt;

- Recently **Novel Agents** approved for RRMM

    - Pomalidomide (IMId)
    - daratumumab (anti CD 38 antibody)
    - Carfilzomib (Proteosome Inhibitor)
    - Panobinostat (HDAc inhibitor)
    
- Major economic burden on individuals and  society

.footnote[
1.  [CA Cancer J Clin 2016;7–30](10.3322/caac.21332)
2.  [S K Kumar, Leukemia, 2012](10.1038/leu.2011.196)]

???

## References

1.  CAAC:CAAC21332
1.  After previous reference

---

class: center, middle, inverse

# Parent Study

### Christopher G. Pelligra, Kejal Parikh, Shien Guo et al. 

### Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United States

_Clinical Therapeutics,
Volume 39, Issue 10,
2017_

&lt;http://www.sciencedirect.com/science/article/pii/S0149291817308998&gt;

---

# Conduct of study

- Compared three protocols

    - Pomalidomide-dexamethasone (POMd): [MM-002 trial](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962162/)
    
    - Single agent Daratumumab (DARA): [SIRIUS trial](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736&amp;#40;15&amp;#41;01120-4/fulltext)
    
    - Single agent Carfilzomib (CARF): [PX-171-003-A1 trial](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123387/)
    
- **Multiple relapsed or refractory** patients (Median previous therapies: 5)

- Absence of head to head comparison trial
    
- **Matching adjusted indirect comparison** done to get **unbiased 
estimate of relative efficacy**

- **Parametric fits** were made for **POMd** arm of MM-002 data and 
**HR were derived** for DARA and CARF from their respective trials

---

# Distribution of second line therapies (in %)

Initial Line   |   POM-d  |   DARA  | CAR   |   LEN-d   |   BORT    |   THAL-d    |   PanVD
---------------|:--------:|:-------:|:-----:|:---------:|:---------:|:-----------:|:--------:
POM-d         |   0       |   7.5   | 38.4  |   22.2    |   17.8    |   6.6       |   7.5
DARA          |   40.2    |   0     | 24.8  |   14.4    |   11.5    |   4.3       |   4.8
CARF          |   50.2    |   6.0   | 0     |   18.0    |   14.4    |   5.4       |   6.0

---

# Definitions of outcome measures

### Progression free survival

Time from randomisation to disease progression (IMWG criteria) or death

--

### Post progression survival

Time from disease progression till death

--

### Fatal progression probability

Per cycle probability that a patient in PF state would die

---
# Definitions of outcome measures

### Premature treatment discontinuation

Time from randomisation till discontinuation of treatment prior to 
disease progression due to unacceptable toxicity, patient's preference 
or other reasons

--

### Adverse Events

4 adverse events included (Grade 3/4, occuring in &gt; 5% of patients on treatment)

- Anemia
- Fatigue
- Neutropenia
- Thrombocytopenia

Percentages converted to monthly incidence rates

---

# Utilities

### Weights assigned to each state for calculating QALM lived

- **PF state:** 0.7 to 0.76

- **PP state decrement:** -0.084 to -0.025

- **AE decrement:** -0.049 to -0.009

---

# State diagram for outcomes

&lt;img src="figs/state_diag.jpg" width="90%" style="display: block; margin: auto;" /&gt;

.center[**28 days cycles**]

---

class: center, middle, inverse

# Present Study

---

class: center, middle, inverse

## Conduct of Study

---

# Outcome parameters

- All outcome parameters taken from the Parent trial

- Adverse event parameters were derived from the percentages 
given in the original trials and converted into **per cycle incidence rates**

- Fatigue was not considered as AE

---

# Economic parameters

- All costings were done with Jan 2018, which was taken as **base time**

- All costings were converted to **per cycle unit costs**

- **Annual inflation rate** of 3.5% to 6% was assumed

- **Annual discount rate** of 3% was used

---

# Subclassification of costs

- **Regimen associated costs** (= Regimen cost + Cost of adjuncts)

- **Cost of prophylaxis** (VTE/Herpes) (= Cost of adjunct)

- **Cost of AEs** (= PRBC txn + Plt txn + GCSF administration + 7 days of 3rd generation cephalosporin [10% of neutropenia])

- **Health care resource cost stratified according to health state** (= Clinical Visits + CBC + Biochemistry + SPEP/SFLC/SIFE + PRBC txn + Plt txn)

---

# Regimen related costs (per cycle)

Regimens     |       Variable Cost (INR), (unit)    | Fixed Cost (INR) 
------------|:-------------------------------------:|:------------:
POM-d       |                   -                 | 20080.00
DARA (cycles 1-2)  | 2400.00, (per kg)              | 4200.00
DARA (cycles 3-6)  | 1200.00, (per kg)              | 2100.00
DARA (cycles &gt; 6)  | 600.00, (per kg)               | 1050.00
CARF (cycle 1)  | 24675.30, (per sq m)              | -
CARF (cycles 2-12)  | 26973.00, (per sq m)          | -
CARF (cycles &gt; 12)  | 17982.00 (per sq m)           | -
LEN-d               | -                             | 15788.00
BORT                | -                             | 45200.00
THAL-d              | -                             | 7568.00
PAN-V-d (cycles 1-8) | -                            | 110280.00
PAN-V-d (cycles &gt; 8) | -                            | 87640.00

---

# Regimen related costs (per cycle)

### Cost of Prophylaxis

- **VTE:** (90% on Aspirin and rest on Enoxaparin) INR 1459.20

- **Antiviral:** INR 360.00

---

# Cost of AEs (per episode)

### Anemia

- 2 units of PRBC transfusion
- **INR 2100.00**

### Neutropenia

- 5 days of GCSF transfusion and 7 days of 3rd generation cephalosporin (10% of neutropenia)
- **INR 5000.00**

### Thrombocytopenia

- 1 unit of SDP/6 units of PRP
- **INR 1800.00**

---

# Health care resource utilisation cost (per cycle)

Headings        |       Unit Cost (INR)         |     PFS (T+)      |     PFS (T-)        | PPS
----------------|:-----------------------------:|-------------------:---------------------:--------
Hematologist clinical visit |   1000.00         |     2000.00       |     1000.00         | 3000.00
Full Blood Count            |   350.00          |     700.00        |     350.00          | 1050.00
Biochemistry (RFT/LFT)      |   1400.00         |     2800.00       |     1400.00         | 4200.00
SPEP                        |   700.00          |     233.33        |     116.67          | 233.33
SIFE                        |   5000.00         |     1666.67       |     833.33          | 1666.67
SFLC                        |   6500.00         |     2166.67       |     1083.33         | 2166.67
**Total**                   |     -             |     **9566.67**   |     **4783.33**     | **12316.67**

---

class: center, middle, inverse

## Creating Individual timelines

_(Computer simulation study)_

---

# Sample Size

- **Horizon of 3 years** was chosen for the simulation (stable economic condition). Patients were censored after 36 months.

- **100 patients** for each of the 3 arms

- Total of 500 simulations were done

&lt;img src="figs/conduct.svg" width="90%" style="display: block; margin: auto;" /&gt;

---

# Few examples (POM-d arm)

&lt;img src="figs/anim_time_line.gif" width="70%" style="display: block; margin: auto;" /&gt;

---

class: center, middle, inverse

## Results

---

# Median Overall Survival (months)

&lt;img src="presentation_actual_files/figure-html/med_os_plot-1.png" width="45%" style="display: block; margin: auto;" /&gt;

&lt;table&gt;
 &lt;thead&gt;
  &lt;tr&gt;
   &lt;th style="text-align:left;"&gt; init_reg &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; mean_median_surv &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 95LCL &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 95UCL &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 25centile &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 75centile &lt;/th&gt;
  &lt;/tr&gt;
 &lt;/thead&gt;
&lt;tbody&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; pomd &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 17.1570 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 13.3333 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 21.3575 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 15.8512 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 18.4071 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; dara &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 17.0114 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 13.5000 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 21.0000 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 15.6667 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 18.3333 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; carf &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 16.7497 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 13.5000 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 20.6667 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 15.5000 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 18.0000 &lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

---

## Overall Survival at 3, 6, 12, 18, 24, 36 months

&lt;img src="presentation_actual_files/figure-html/os_plot-1.png" width="70%" style="display: block; margin: auto;" /&gt;

---

# Median Progression Free Survival (months)

&lt;img src="presentation_actual_files/figure-html/med_pfs_plot-1.png" width="45%" style="display: block; margin: auto;" /&gt;

&lt;table&gt;
 &lt;thead&gt;
  &lt;tr&gt;
   &lt;th style="text-align:left;"&gt; init_reg &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; mean_median_pfs &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 95LCL &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 95UCL &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 25centile &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 75centile &lt;/th&gt;
  &lt;/tr&gt;
 &lt;/thead&gt;
&lt;tbody&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; pomd &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 17.1425 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 13.3333 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 21.3575 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 15.8000 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 18.4000 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; dara &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 17.0007 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 13.5000 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 20.8812 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 15.6667 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 18.2708 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; carf &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 16.7488 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 13.5000 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 20.6667 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 15.5000 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 18.0000 &lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

---

## PFS at 3, 6, 12, 18, 24, 36months

&lt;img src="presentation_actual_files/figure-html/pfs_plot-1.png" width="70%" style="display: block; margin: auto;" /&gt;

---

# Progression Free Life Months (PFLM)

&lt;img src="presentation_actual_files/figure-html/pflm_plot-1.png" width="45%" style="display: block; margin: auto;" /&gt;

&lt;table&gt;
 &lt;thead&gt;
  &lt;tr&gt;
   &lt;th style="text-align:left;"&gt; init_reg &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; med_pfm &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 95LCL &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 95UCL &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 25tile &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 75tile &lt;/th&gt;
  &lt;/tr&gt;
 &lt;/thead&gt;
&lt;tbody&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; carf &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 4 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 3 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 4 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 3 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 4.0 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; dara &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 4 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 3 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 5 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 4 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 4.0 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; pomd &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 4 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 3 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 5 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 4 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 4.5 &lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

---

# Quality Adjusted Life Months (QALM)

&lt;img src="presentation_actual_files/figure-html/qalm_plot-1.png" width="45%" style="display: block; margin: auto;" /&gt;

&lt;table&gt;
 &lt;thead&gt;
  &lt;tr&gt;
   &lt;th style="text-align:left;"&gt; init_reg &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; med_pfm &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 95LCL &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 95UCL &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 25tile &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 75tile &lt;/th&gt;
  &lt;/tr&gt;
 &lt;/thead&gt;
&lt;tbody&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; carf &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 11.0293 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 8.8127 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 13.7548 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 10.2393 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 11.9131 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; dara &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 11.2297 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 9.0112 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 13.7750 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 10.3453 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 12.1640 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; pomd &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 11.3767 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 8.9134 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 14.0928 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 10.5132 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 12.2253 &lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

---

class: center, middle

## No difference in clinical efficacy between all three arms

---

# Regimen associated Discounted Cost

&lt;img src="presentation_actual_files/figure-html/reg_cost_plot-1.png" width="45%" style="display: block; margin: auto;" /&gt;

&lt;table&gt;
 &lt;thead&gt;
  &lt;tr&gt;
   &lt;th style="text-align:left;"&gt; init_reg &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; med_cost_month &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 95LCL &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 95UCL &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 25tile &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 75tile &lt;/th&gt;
  &lt;/tr&gt;
 &lt;/thead&gt;
&lt;tbody&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; dara &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 55143.72 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 48638.94 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 63355.32 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 52726.57 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 57723.10 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; pomd &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 32370.84 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 21656.73 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 37982.45 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 29379.04 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 34890.15 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; carf &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 25769.79 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 23650.16 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 29015.03 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 24905.19 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 26911.36 &lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

---

# Cost per QALM

&lt;img src="presentation_actual_files/figure-html/cost_qalm_plot-1.png" width="45%" style="display: block; margin: auto;" /&gt;

&lt;table&gt;
 &lt;thead&gt;
  &lt;tr&gt;
   &lt;th style="text-align:left;"&gt; init_reg &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; med_cost_qalm &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 95LCL &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 95UCL &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 25tile &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; 75tile &lt;/th&gt;
  &lt;/tr&gt;
 &lt;/thead&gt;
&lt;tbody&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; dara &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 86609.35 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 76026.52 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 99518.78 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 82721.20 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 90635.68 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; pomd &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 55897.85 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 44735.16 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 61518.81 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 51986.42 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 58222.93 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; carf &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 41495.18 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 37974.16 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 47988.91 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 40129.71 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 43575.42 &lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

---

# Conclusions

- **Daratumumab** has the highest median cost per QALM lived of **INR 86609.00 (95% CI: 76027.00 - 99519.00)**. Incremental cost per QALM lived is **INR 30711.00 than POM-d**

- **Carfilzomib** has the lowest median cost per QALM lived of **INR 41495.00 (95% CI: 37974.00 - 47989.00)**. Incremental cost per QALM lived is **INR (- 14403.00) than POM-d**

- **Pomalidomide dexamethasone** has the median cost per QALM lived of **INR 55897.85 (95% CI: 44735.16 - 61518.81)**
---

class: center, middle, inverse

# Thank You
    </textarea>
<script src="libs/remark-latest.min.js"></script>
<script>var slideshow = remark.create({
"highlightStyle": "github",
"highlightLines": true,
"countIncrementalSlides": false
});
if (window.HTMLWidgets) slideshow.on('afterShowSlide', function (slide) {
  window.dispatchEvent(new Event('resize'));
});
(function() {
  var d = document, s = d.createElement("style"), r = d.querySelector(".remark-slide-scaler");
  if (!r) return;
  s.type = "text/css"; s.innerHTML = "@page {size: " + r.style.width + " " + r.style.height +"; }";
  d.head.appendChild(s);
})();</script>

<script type="text/x-mathjax-config">
MathJax.Hub.Config({
  tex2jax: {
    skipTags: ['script', 'noscript', 'style', 'textarea', 'pre']
  }
});
</script>
<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
(function () {
  var script = document.createElement('script');
  script.type = 'text/javascript';
  script.src  = 'https://cdn.bootcss.com/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML';
  if (location.protocol !== 'file:' && /^https?:/.test(script.src))
    script.src  = script.src.replace(/^https?:/, '');
  document.getElementsByTagName('head')[0].appendChild(script);
})();
</script>
  </body>
</html>
